Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections : Updates, Challenges, and Future Perspectives
The unique structural architecture of the peptidoglycan allows for the stratification of bacteria as either Gram-negative or Gram-positive, which makes bacterial cells distinguishable from mammalian cells. This classification has received attention as a potential target for diagnostic and therapeutic purposes. Bacteria's ability to metabolically integrate peptidoglycan precursors during cell wall biosynthesis and recycling offers an opportunity to target and image pathogens in their biological state. This Review explores the peptidoglycan biosynthesis for bacteria-specific targeting for infection imaging. Current and potential radiolabeled peptidoglycan precursors for bacterial infection imaging, their development status, and their performance in vitro and/or in vivo are highlighted. We conclude by providing our thoughts on how to shape this area of research for future clinical translation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ACS infectious diseases - 10(2024), 2 vom: 09. Feb., Seite 270-286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koatale, Palesa C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacteria |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsinfecdis.3c00443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367808498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367808498 | ||
| 003 | DE-627 | ||
| 005 | 20240222091751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsinfecdis.3c00443 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM367808498 | ||
| 035 | |a (NLM)38290525 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koatale, Palesa C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections |b Updates, Challenges, and Future Perspectives |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The unique structural architecture of the peptidoglycan allows for the stratification of bacteria as either Gram-negative or Gram-positive, which makes bacterial cells distinguishable from mammalian cells. This classification has received attention as a potential target for diagnostic and therapeutic purposes. Bacteria's ability to metabolically integrate peptidoglycan precursors during cell wall biosynthesis and recycling offers an opportunity to target and image pathogens in their biological state. This Review explores the peptidoglycan biosynthesis for bacteria-specific targeting for infection imaging. Current and potential radiolabeled peptidoglycan precursors for bacterial infection imaging, their development status, and their performance in vitro and/or in vivo are highlighted. We conclude by providing our thoughts on how to shape this area of research for future clinical translation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bacteria | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a molecular imaging | |
| 650 | 4 | |a nuclear medicine | |
| 650 | 4 | |a peptidoglycan | |
| 650 | 4 | |a precursor | |
| 650 | 4 | |a tracer development | |
| 650 | 7 | |a Peptidoglycan |2 NLM | |
| 700 | 1 | |a Welling, Mick M |e verfasserin |4 aut | |
| 700 | 1 | |a Ndlovu, Honest |e verfasserin |4 aut | |
| 700 | 1 | |a Kgatle, Mankgopo |e verfasserin |4 aut | |
| 700 | 1 | |a Mdanda, Sipho |e verfasserin |4 aut | |
| 700 | 1 | |a Mdlophane, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Okem, Ambrose |e verfasserin |4 aut | |
| 700 | 1 | |a Takyi-Williams, John |e verfasserin |4 aut | |
| 700 | 1 | |a Sathekge, Mike M |e verfasserin |4 aut | |
| 700 | 1 | |a Ebenhan, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS infectious diseases |d 2015 |g 10(2024), 2 vom: 09. Feb., Seite 270-286 |w (DE-627)NLM248280775 |x 2373-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:2 |g day:09 |g month:02 |g pages:270-286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsinfecdis.3c00443 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 2 |b 09 |c 02 |h 270-286 | ||